Although it does not receive the same level of fanfare as other classes of pharmacotherapies in the cardiometabolic health space, the development of the cardiac myosin inhibitor class represents a significant advancement in the management of hypertrophic cardiomyopathy and, potentially, cardiovascular medicine as a whole in recent years. In April 2022, the FDA made history with the approval of mavacamten (Camzyos) for treatment of adults with symptomatic New York Heart Association class II-III obstructive HCM to improve functional capacity and symptoms based on data from the phase 3 EXPLORER-HCM trial Continue reading →